Additive and Antagonistic Effects Among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity
Journal Title: Diabetes Research – Open Journal - Year 2015, Vol 1, Issue 2
Abstract
Objective: The Angiotensin-II receptor blocker telmisartan and sulfonylurea glimepiride may have clinical usefulness as partial agonists of PPARg. We investigated additive and antagonistic effects among combinations of telmisartan, glimepiride, and the Thiazolidinedione (TZD) selective PPARg agonist pioglitazone on transcriptional activity of PPARg. Materials/Methods: The receptors of pCMX-PPARg and pCMX-RXR, and PPRE-Luc reporter gene were transfected into CV1 cells, and treated with following agents, and luciferace assay was performed. Moreover, mammalian two-hybrid assay was done using GAL4 responsive reporter tk-MH100(UAS)×4-Luc and the chimeric receptor GAL4-PPARg. Results: Telmisartan increased transactivation of PPARg dose dependently. Activation by telmisartan 10 µM was 58.8% of that by pioglitazone 10 µM. Glimepiride also increased transactivation of PPARg dose dependently. Activation by glimepiride 10 µM was 49.8% of that by pioglitazone 10 µM. Addition of telmisartan 5 µM significantly enhanced transactivation by glimepiride 10 and 50 µM. Moreover, addition of pioglitazone 0.5 µM significantly enhanced transactivation by glimepiride 10 and 50 µM. Mammalian two-hybrid assay showed additive effect between glimepiride and telmisartan on binding of SRC-1 to PPARg. On the other hand, addition of glimepiride 10 and 50 µM reduced transactivation by pioglitazone 5 µM to 74% and 70%, respectively. Conclusion: Partial agonists of PPARg additively enhanced transactivation by other agonists, whereas high concentration of partial agonists reduced transactivation by full agonist antagonistically.
Authors and Affiliations
Daisuke Tsuriya
Keywords
Related Articles
- EP ID EP550007
- DOI 10.17140/DROJ-1-105
- Views 158
- Downloads 0
Do we Need New Therapies for Diabetes?
Diabetes research and practice cluster (drug developers, payers, regulators and physicians) often (and especially in recent times) question the need of new therapies. Why would we need new therapies nowadays, when we hav...
Rapid Improvement of Blood Glucose Level after Prosthetic Mandibular Advancement in a Patient with Diabetes Mellitus and Obstructive Sleep Apnea
Introduction: Obstructive Sleep Apnea Syndrome (OSAS) is often associated with impaired glucose metabolism. However, the effects of Prosthetic Mandibular Advancement (PMA) on blood glucose levels and insulin resistance r...
Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases
Acute increase of type 2 diabetes mellitus (T2DM) is a serious medical problem. Recently, an agent known as Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was developed for T2DM which has remarkable efficacy and s...
Apelin Gene Therapy Increases Autophagy Via Activation of Sirtuin 3 in Diabetic Heart
Heart failure is the leading cause of death in diabetic patients. Recently we showed that apelin gene therapy attenuates heart failure following myocardial infarction. This study further explored the potential mechanisms...
Low Protein Brown Rice for Preventing Progression of CKD and DKD to End Stage Renal Failure
Chronic kidney disease (CKD) is pervasive into aging society, affecting permanent implications on patients’ life. Approximately 10% of the global population has CKD, and millions die each year. The prevalence of CKD was...